糖尿病视网膜病变患者接受舒洛地特治疗后眼底脉络膜厚度的长期纵向分析

IF 0.1 Q4 OPHTHALMOLOGY
Chang Min Cha, Jae Wan Lim, C. Kim, Seung Uk Lee, Sang Joon Lee
{"title":"糖尿病视网膜病变患者接受舒洛地特治疗后眼底脉络膜厚度的长期纵向分析","authors":"Chang Min Cha, Jae Wan Lim, C. Kim, Seung Uk Lee, Sang Joon Lee","doi":"10.3341/jkos.2023.64.12.1208","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the two-year longitudinal changes in subfoveal choroidal thickness (CT) following sulodexide treatment in patients with diabetic retinopathy.Methods: Thirty-eight eyes from patients with diabetic retinopathy, followed for a minimum of two years after sulodexide administration, were included. Subfoveal CT, measured using optical coherence tomography, was analyzed prospectively. Variables including age, sex, duration of diabetes mellitus, HbA1c, blood pressure, sulodexide treatment duration, refractive error, axial length, central macular thickness (CMT), visual acuity, laser photocoagulation, and intravitreal anti-vascular endothelial growth factor injections were evaluated for potential effects on CT. CMT, subfoveal CT, and choroidal vascularity index were compared at baseline and at 6, 12, and 24 months after sulodexide.Results: Of the 38 eyes, 10 belonged to males and 28 to females. The mean data were as follows: age, 67.18 ± 8.87 years; duration of diabetes, 18.11 ± 7.57 years; HbA1c, 8.76 ± 1.60 mmol/L; systolic blood pressure, 134.69 ± 14.68 mmHg; diastolic blood pressure, 73.72 ± 11.90 mmHg; duration of sulodexide, 25.79 ± 3.17 months; refractive error, 0.22 ± 2.19 diopters (D); and axial length, 23.32 ± 0.89 mm. During the observation period, 15 eyes underwent laser photocoagulation and 17 eyes received intravitreal anti-vascular endothelial growth factor injections. The mean subfoveal CT was 216.00 ± 64.23 μm before sulodexide administration and increased to 223.87 ± 62.18 μm, 225.53 ± 62.02 μm, and 225.76 ± 63.62 μm at 6, 12, and 24 months, respectively (p = 0.0377, p = 0.0159, p = 0.0135). The CMT was 318.14 ± 102.28 μm initially and changed to 313.08 ± 77.47 μm, 314.97 ± 88.32 μm, and 320.03 ± 97.36 μm at the aforementioned intervals, with no significant variation (p = 0.904, p = 0.736, p = 0.892).Conclusions: Sulodexide administration led to a significant rise in subfoveal CT over a 2-year follow-up. This change in CT was not mirrored in the CMT.","PeriodicalId":17341,"journal":{"name":"Journal of The Korean Ophthalmological Society","volume":"130 4","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-term Longitudinal Analysis of Subfoveal Choroidal Thickness Following Sulodexide Treatment in Diabetic Retinopathy Patients\",\"authors\":\"Chang Min Cha, Jae Wan Lim, C. Kim, Seung Uk Lee, Sang Joon Lee\",\"doi\":\"10.3341/jkos.2023.64.12.1208\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To evaluate the two-year longitudinal changes in subfoveal choroidal thickness (CT) following sulodexide treatment in patients with diabetic retinopathy.Methods: Thirty-eight eyes from patients with diabetic retinopathy, followed for a minimum of two years after sulodexide administration, were included. Subfoveal CT, measured using optical coherence tomography, was analyzed prospectively. Variables including age, sex, duration of diabetes mellitus, HbA1c, blood pressure, sulodexide treatment duration, refractive error, axial length, central macular thickness (CMT), visual acuity, laser photocoagulation, and intravitreal anti-vascular endothelial growth factor injections were evaluated for potential effects on CT. CMT, subfoveal CT, and choroidal vascularity index were compared at baseline and at 6, 12, and 24 months after sulodexide.Results: Of the 38 eyes, 10 belonged to males and 28 to females. The mean data were as follows: age, 67.18 ± 8.87 years; duration of diabetes, 18.11 ± 7.57 years; HbA1c, 8.76 ± 1.60 mmol/L; systolic blood pressure, 134.69 ± 14.68 mmHg; diastolic blood pressure, 73.72 ± 11.90 mmHg; duration of sulodexide, 25.79 ± 3.17 months; refractive error, 0.22 ± 2.19 diopters (D); and axial length, 23.32 ± 0.89 mm. During the observation period, 15 eyes underwent laser photocoagulation and 17 eyes received intravitreal anti-vascular endothelial growth factor injections. The mean subfoveal CT was 216.00 ± 64.23 μm before sulodexide administration and increased to 223.87 ± 62.18 μm, 225.53 ± 62.02 μm, and 225.76 ± 63.62 μm at 6, 12, and 24 months, respectively (p = 0.0377, p = 0.0159, p = 0.0135). The CMT was 318.14 ± 102.28 μm initially and changed to 313.08 ± 77.47 μm, 314.97 ± 88.32 μm, and 320.03 ± 97.36 μm at the aforementioned intervals, with no significant variation (p = 0.904, p = 0.736, p = 0.892).Conclusions: Sulodexide administration led to a significant rise in subfoveal CT over a 2-year follow-up. This change in CT was not mirrored in the CMT.\",\"PeriodicalId\":17341,\"journal\":{\"name\":\"Journal of The Korean Ophthalmological Society\",\"volume\":\"130 4\",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2023-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of The Korean Ophthalmological Society\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3341/jkos.2023.64.12.1208\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of The Korean Ophthalmological Society","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3341/jkos.2023.64.12.1208","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估舒洛地特治疗糖尿病视网膜病变患者两年后眼底脉络膜厚度(CT)的纵向变化:方法:纳入糖尿病视网膜病变患者的 38 只眼睛,在服用舒洛地特至少两年后进行随访。使用光学相干断层扫描测量眼底 CT,并对其进行前瞻性分析。评估了年龄、性别、糖尿病持续时间、HbA1c、血压、舒洛地特治疗时间、屈光不正、轴向长度、黄斑中心厚度(CMT)、视力、激光光凝和玻璃体内抗血管内皮生长因子注射等变量对 CT 的潜在影响。比较了基线时以及舒洛地特治疗后 6、12 和 24 个月时的 CMT、眼底 CT 和脉络膜血管指数:38只眼睛中,男性10只,女性28只。平均数据如下:年龄(67.18±8.87)岁;糖尿病病程(18.11±7.57)年;HbA1c(8.76±1.60)mmol/L;收缩压(134.69±14.68)mmHg;舒张压(73.72±11.90)mmHg;服用舒洛地特的时间(25.79±3.17)个月;屈光不正(0.22±2.19)屈光度(D);轴长(23.32±0.89)mm。在观察期间,15 只眼睛接受了激光光凝,17 只眼睛接受了玻璃体内抗血管内皮生长因子注射。服用舒洛地特前,平均眼底 CT 为 216.00 ± 64.23 μm,6、12 和 24 个月时分别增至 223.87 ± 62.18 μm、225.53 ± 62.02 μm、225.76 ± 63.62 μm(p = 0.0377、p = 0.0159、p = 0.0135)。CMT最初为318.14±102.28 μm,在上述时间间隔内分别变为313.08±77.47 μm、314.97±88.32 μm和320.03±97.36 μm,无显著变化(p = 0.904、p = 0.736、p = 0.892):结论:服用舒洛地特会导致眼底 CT 在两年的随访期间显著上升。结论:服用舒洛地特会导致眼底 CT 在 2 年的随访期间明显升高,而 CT 的这种变化并没有反映在 CMT 中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Long-term Longitudinal Analysis of Subfoveal Choroidal Thickness Following Sulodexide Treatment in Diabetic Retinopathy Patients
Purpose: To evaluate the two-year longitudinal changes in subfoveal choroidal thickness (CT) following sulodexide treatment in patients with diabetic retinopathy.Methods: Thirty-eight eyes from patients with diabetic retinopathy, followed for a minimum of two years after sulodexide administration, were included. Subfoveal CT, measured using optical coherence tomography, was analyzed prospectively. Variables including age, sex, duration of diabetes mellitus, HbA1c, blood pressure, sulodexide treatment duration, refractive error, axial length, central macular thickness (CMT), visual acuity, laser photocoagulation, and intravitreal anti-vascular endothelial growth factor injections were evaluated for potential effects on CT. CMT, subfoveal CT, and choroidal vascularity index were compared at baseline and at 6, 12, and 24 months after sulodexide.Results: Of the 38 eyes, 10 belonged to males and 28 to females. The mean data were as follows: age, 67.18 ± 8.87 years; duration of diabetes, 18.11 ± 7.57 years; HbA1c, 8.76 ± 1.60 mmol/L; systolic blood pressure, 134.69 ± 14.68 mmHg; diastolic blood pressure, 73.72 ± 11.90 mmHg; duration of sulodexide, 25.79 ± 3.17 months; refractive error, 0.22 ± 2.19 diopters (D); and axial length, 23.32 ± 0.89 mm. During the observation period, 15 eyes underwent laser photocoagulation and 17 eyes received intravitreal anti-vascular endothelial growth factor injections. The mean subfoveal CT was 216.00 ± 64.23 μm before sulodexide administration and increased to 223.87 ± 62.18 μm, 225.53 ± 62.02 μm, and 225.76 ± 63.62 μm at 6, 12, and 24 months, respectively (p = 0.0377, p = 0.0159, p = 0.0135). The CMT was 318.14 ± 102.28 μm initially and changed to 313.08 ± 77.47 μm, 314.97 ± 88.32 μm, and 320.03 ± 97.36 μm at the aforementioned intervals, with no significant variation (p = 0.904, p = 0.736, p = 0.892).Conclusions: Sulodexide administration led to a significant rise in subfoveal CT over a 2-year follow-up. This change in CT was not mirrored in the CMT.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
126
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信